Drugs / Darizmetinib
Darizmetinib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07612007 | Sep 2026 → Aug 2028 expected | colorectal carcinoma, metastatic neoplasm | Mayo Clinic | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Darizmetinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07612007 ↗ |
| Known as | HRX-0215 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4795907 ↗ |
| Known as | LN-3348 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4795907 ↗ |
| Modality | Small molecule | — CHEMBL4795907 ↗ |